BlackRock reports 6.7% stake in Janux Therapeutics
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership of common stock of Janux Therapeutics, Inc. As of June 30, 2026, BlackRock reported beneficial ownership of 4,098,457 shares of Janux common stock, representing 6.7% of the outstanding class.
BlackRock reported sole voting power over 4,024,396 shares and sole dispositive power over 4,098,457 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no individual client holds more than five percent of Janux’s outstanding common shares.
Key Figures
Key Terms
Schedule 13G regulatory
beneficially owned financial
sole voting power financial
sole dispositive power financial
percent of class financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who ultimately benefits from BlackRock’s Janux Therapeutics (JANX) holdings?
What type of securities are covered in BlackRock’s Schedule 13G/A for Janux (JANX)?
What is the reporting structure for BlackRock’s Janux (JANX) ownership in this filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.